240 related articles for article (PubMed ID: 31422383)
1. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Ji XL; He M
Aging (Albany NY); 2019 Aug; 11(15):5848-5863. PubMed ID: 31422383
[TBL] [Abstract][Full Text] [Related]
2. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
[TBL] [Abstract][Full Text] [Related]
3. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
5. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
6. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
8. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.
Chen C; Zhang H; Yu Y; Huang Q; Wang W; Niu J; Lou J; Ren T; Huang Y; Guo W
Aging (Albany NY); 2021 Jun; 13(13):17901-17913. PubMed ID: 34170850
[TBL] [Abstract][Full Text] [Related]
10. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
11. 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway.
Park KR; Yun HM; Quang TH; Oh H; Lee DS; Auh QS; Kim EC
Oncotarget; 2016 Feb; 7(6):6960-71. PubMed ID: 26755649
[TBL] [Abstract][Full Text] [Related]
12. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
[TBL] [Abstract][Full Text] [Related]
13. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
14. Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.
Zhang C; Ma K; Li WY
Drug Des Devel Ther; 2019; 13():4075-4090. PubMed ID: 31824138
[TBL] [Abstract][Full Text] [Related]
15. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.
Mao M; Zhang T; Wang Z; Wang H; Xu J; Yin F; Wang G; Sun M; Wang Z; Hua Y; Cai Z
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1214-1225. PubMed ID: 30659925
[TBL] [Abstract][Full Text] [Related]
16. Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models.
Miao J; Chen S; Cao H; Ding Z; Li Y; Wang W; Nundlall K; Deng Y; Li J
Mol Carcinog; 2024 Jun; 63(6):1133-1145. PubMed ID: 38426797
[TBL] [Abstract][Full Text] [Related]
17. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.
Jia F; Liu Y; Dou X; Du C; Mao T; Liu X
Oxid Med Cell Longev; 2022; 2022():8245614. PubMed ID: 35116094
[TBL] [Abstract][Full Text] [Related]
18. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.
Zhang T; Li J; Yin F; Lin B; Wang Z; Xu J; Wang H; Zuo D; Wang G; Hua Y; Cai Z
Oncogene; 2017 Nov; 36(47):6627-6639. PubMed ID: 28783167
[TBL] [Abstract][Full Text] [Related]
19. Elemene inhibits osteosarcoma growth by suppressing the renin‑angiotensin system signaling pathway.
Ding L; Zhang G; Hou Y; Chen J; Yin Y
Mol Med Rep; 2018 Jan; 17(1):1022-1030. PubMed ID: 29115494
[TBL] [Abstract][Full Text] [Related]
20. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
